Company intelligence / Profile preview

Shanghai Shangyao Ruier Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

As of late 2023, SPH Ruier oversees a rare disease R&D platform with at least 16 ongoing projects across rare oncology, neurology, endocrinology, cardiovascular, and metabolic conditions. Notable clinical achievements: one program in Phase 2 (ALS), one in Phase 3 (acute urticaria), and several products approaching/at commercialization

Therapeutic areas: EndocrinologyMetabolic DisordersRare DiseasesHematologyDermatologyCardiovascularOncologyNeurology
Modalities: Small moleculeBiologicMonoclonal antibodyCell therapyGene therapy
Industry: Biotech

Partnerships

Kaichuan Pharmaceuticals (SRD4610)Kexin Bicheng (SRD5211)Shanghai Ruijin Hospital (SRD6214)

Beyond the preview

Go deeper on Shanghai Shangyao Ruier Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Shangyao Ruier Pharmaceutical.

Explore the full profile